Characterisation of the 5 kDa growth hormone isoform

References

• Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol (Oxf) 2006; 64: 444–449
   Google Scholar
• Alam KS, Morimoto M, Yoshizato H, Fujikawa T, Furukawa K, Tanaka M, Nakashima K. Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro. J Biotechnol 1998; 65: 183–190
   PubMedGoogle Scholar
• Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J 2006; 82: 24–30
   PubMed Web of Science ®Google Scholar
• Baumann G. Growth hormone heterogeneity in human pituitary and plasma. Horm Res 1999; 51(Suppl 1)2–6
   PubMedGoogle Scholar
• Beavis RC, Chait BT. Rapid, sensitive analysis of protein mixtures by mass spectrometry. Proc Natl Acad Sci USA 1990; 87: 6873–6877
   PubMed Web of Science ®Google Scholar
• Bennion BJ, Daggett V. The molecular basis for the chemical denaturation of proteins by urea. Proc Natl Acad Sci USA 2003; 100: 5142–5147
   PubMed Web of Science ®Google Scholar
• Bonroy K, Frederix F, Reekmans G, Dewolf E, De Palma R, Borghs G, Declerck P, Goddeeris B. Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers. J Immunol Methods 2006; 312: 167–181
   PubMed Web of Science ®Google Scholar
• Boyle PJ, Freeman JS. Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus. J Am Osteopath Assoc 2007; 107(Suppl)S10–S16
   Google Scholar
• Buck M. Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins. Q Rev Biophys 1998; 31: 297–355
   PubMed Web of Science ®Google Scholar
• De Palo EF, De FV, Gatti R, Spinella P. Growth hormone isoforms and segments/fragments: molecular structure and laboratory measurement. Clin Chim Acta 2005
   Google Scholar
• Dienys G, Sereikaite J, Gavenas G, Kvederas R, Bumelis VA. Cross-linking of protein subunits by 1,3,5-triacryloyl-hexahydro-s-triazine. Bioconjug Chem 1998; 9: 744–748
   Google Scholar
• Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990; 35: 161–214
   PubMedGoogle Scholar
• Fink AL, Calciano LJ, Goto Y, Kurotsu T, Palleros DR. Classification of acid denaturation of proteins: intermediates and unfolded states. Biochemistry 1994; 33: 12504–12511
   PubMed Web of Science ®Google Scholar
• Frigeri LG, Teguh C, Ling N, Wolff GL, Lewis UJ. Increased sensitivity of adipose tissue to insulin after in vivo treatment of yellow Avy/A obese mice with amino-terminal peptides of human growh hormone. Endocrinology 1988; 122: 2940–2945
   PubMedGoogle Scholar
• Ge G, Fernandez CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci USA 2007; 104: 10010–10015
   PubMedGoogle Scholar
• Gobom J, Nordhoff E, Mirgorodskaya E, Ekman R, Roepstorff P. Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 1999; 34: 105–116
   PubMed Web of Science ®Google Scholar
• Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000; 21: 1037–1053
   PubMed Web of Science ®Google Scholar
• Haro LS, Singh RN, Lewis UJ, Martinez AO, Galosy SS, Staten NR, Krivi GG. Human growth hormone deletion mutant (hGH44-191) binds with high affinity to lactogenic receptors but not to somatogenic receptors. Biochem Biophys Res Commun 1996; 222: 421–426
   PubMedGoogle Scholar
• Hashimoto Y, Ikeda I, Ikeda M, Takahashi Y, Hosaka M, Uchida H, Kono N, Fukui H, Makino T, Honjo M. Construction of a specific and sensitive sandwich enzyme immunoassay for 20 kDa human growth hormone. J Immunol Methods 1998; 221: 77–85
   PubMed Web of Science ®Google Scholar
• Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab 2000; 279: E501–E507
   Google Scholar
• Hettiarachchi M, Watkinson A, Leung KC, Sinha YN, Ho KK, Kraegen EW. Human growth hormone fragment (hGH44-91) produces insulin resistance and hyperinsulinemia but is less potent than 22kDa hGH in the rat. Endocrine 1997; 6: 47–52
   PubMedGoogle Scholar
• Hubbard SJ. The structural aspects of limited proteolysis of native proteins. Biochim Biophys Acta 1998; 1382: 191–206
   PubMed Web of Science ®Google Scholar
• Jeoung DI, Allen DL, Guller S, Yen V, Sonenberg M. Mitogenic and receptor activities of human growth hormone 108-129. J Biol Chem 1993; 268: 22520–22524
   Google Scholar
• Johnsson B, Lofas S, Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem 1991; 198: 268–277
   PubMed Web of Science ®Google Scholar
• Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970; 34: 595–598
   PubMed Web of Science ®Google Scholar
• Kasimova MR, Kristensen SM, Howe PW, Christensen T, Matthiesen F, Petersen J, Sorensen HH, Led JJ. NMR studies of the backbone flexibility and structure of human growth hormone: a comparison of high and low pH conformations. J Mol Biol 2002; 318: 679–695
   PubMedGoogle Scholar
• Kennett RG. Monoclonal antibodies. Hybrid myelomas–a revolution in serology and immunogenetics. Am J Hum Genet 1979; 31: 539–547
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Otsuki N, Kishi T, Micheal IP, Obiezu CV, Borgono CA, Takehara K, Jayakumar A, Wu HK, Clayman GL, Diamandis EP. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. Clin Chim Acta 2007; 377: 228–236
   PubMed Web of Science ®Google Scholar
• Lewis UJ, Lewis LJ, Salem MA, Staten NR, Galosy SS, Krivi GG. A recombinant-DNA-derived modification of human growth hormone (hGH44-191) with enhanced diabetogenic activity. Mol Cell Endocrinol 1991; 78: 45–54
   PubMedGoogle Scholar
• Lewis UJ, Sinha YN, Haro LS. Variant forms and fragments of human growth hormone in serum. Acta Paediatr 1994, Suppl 399: 29–31
   Google Scholar
• Lewis UJ, Sinha YN, Lewis GP. Structure and properties of members of the hGH family: a review. Endocr J 2000; 47(Suppl)S1–S8
   PubMedGoogle Scholar
• Lopez-Guajardo CC, Armstrong LS, Jordan L, Staten NR, Krivi GG, Martinez AO, Haro LS. Generation, characterization and utilization of anti-human growth hormone 1-43, (hGH1-43), monoclonal antibodies in an ELISA. J Immunol Methods 1998; 215: 179–185
   PubMedGoogle Scholar
• Ohkura K, Hori H. Analyses of insulin-potentiating fragments of human growth hormone by computative simulation: essential unit for insulin-involved biological responses. Bioorg Med Chem 2000; 8: 1733–1740
   PubMed Web of Science ®Google Scholar
• Park C, Marqusee S. Probing the high energy states in proteins by proteolysis. J Mol Biol 2004; 343: 1467–1476
   Google Scholar
• Popii V, Baumann G. Laboratory measurement of growth hormone. Clin Chim Acta 2004; 350: 1–16
   PubMed Web of Science ®Google Scholar
• Rosenfalck AM, Maghsoudi S, Fisker S, Jorgensen JO, Christiansen JS, Hilsted J, Volund AA, Madsbad S. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000; 85: 4173–4181
   PubMed Web of Science ®Google Scholar
• Rowlinson SW, Waters MJ, Lewis UJ, Barnard R. Human growth hormone fragments 1-43 and 44-191: in vitro somatogenic activity and receptor binding characteristics in human and nonprimate systems. Endocrinology 1996; 137: 90–95
   PubMed Web of Science ®Google Scholar
• Rupp B. http://www.ruppweb.org/cd/cdtutorial.htm 1996.
   Google Scholar
• Ryther RC, McGuinness LM, Phillips JA, III, Moseley CT, Magoulas CB, Robinson IC, Patton JG. Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II. Hum Genet 2003; 113: 140–148
   PubMed Web of Science ®Google Scholar
• Salem MA. Effects of the amino-terminal portion of human growth hormone on glucose clearance and metabolism in normal, diabetic, hypophysectomized, and diabetic-hypophysectomized rats. Endocrinology 1988; 123: 1565–1576
   PubMedGoogle Scholar
• Salem MA, Wolff GL. Potentiation of response to insulin and anti-insulin action by two human pituitary peptides in lean agouti A/a, obese yellow Avy/A, and C57BL/6J-ob/ob mice. Proc Soc Exp Biol Med 1989; 191: 113–123
   PubMedGoogle Scholar
• Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. Obes Res 2003; 11: 170–175
   PubMedGoogle Scholar
• Shimizu T, Murakami Y, Nishiki M, Koshimura K, Oki Y, Kato Y. Contents and release of human growth hormone1-43 (hGH1-43) in human pituitary glands and hGH-producing pituitary adenoma cells. Biomed Res 2004; 25: 141–146
   Google Scholar
• Singh RNP, Seavey BK, Lewis LJ, Lewis UJ. Human growth hormone peptide 1-43: isolation from pituitary glands. J Protein Chem 1983; 2: 425–436
   Google Scholar
• Sinha YN, Jacobsen BP. Human growth hormone (hGH)-(44-191), a reportedly diabetogenic fragment of hGH, circulates in human blood: measurement by radioimmunoassay. J Clin Endocrinol Metab 1994; 78: 1411–1418
   PubMedGoogle Scholar
• Spolaore B, Polverino DL, Zambonin M, Fontana A. Limited proteolysis of human growth hormone at low pH: isolation, characterization, and complementation of the two biologically relevant fragments 1-44 and 45-191. Biochemistry 2004; 43: 6576–6586
   PubMedGoogle Scholar
• Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 1999; 96: 1246–1251
   PubMed Web of Science ®Google Scholar
• Warner MD, Sinha YN, Peabody CA. Growth hormone and prolactin variants in normal subjects. Relative proportions in morning and afternoon samples. Horm Metab Res 1993; 25: 425–429
   PubMedGoogle Scholar
• Wroblewski VJ, Kaiser RE, Becker GW. Proteolysis of human growth hormone by rat thyroid gland in vitro: application of electrospray mass spectrometry and N-terminal sequencing to elucidate a metabolic pathway. Pharm Res 1993; 10: 1106–1114
   PubMedGoogle Scholar
• Yang JT, Wu CS, Martinez HM. Calculation of protein conformation from circular dichroism. Methods Enzymol 1986; 130: 208–269
   PubMed Web of Science ®Google Scholar
• Yuen K, Ong K, Husbands S, Chatelain P, Fryklund L, Gluckman P, Ranke M, Cook D, Rosenfeld R, Wass J, Dunger D. The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults. J Clin Endocrinol Metab 2002; 87: 1989–1995
   Google Scholar
• Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, Fryklund L, Murgatroyd PR, Dunger DB. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 2005; 63: 428–436
   PubMed Web of Science ®Google Scholar
• Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha RR. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003; 278: 22418–22423
   PubMed Web of Science ®Google Scholar